Regentis Biomaterials
Implantable Hydrogel Platform for Tissue Regeneration
Company Overview
Snapshot
Founded in September 2004 by Prof. Dror Seliktar, Regentis Biomaterials operates with 1–10 employees. The company has raised $43.5 million across 4 funding rounds from 8 investors. In September 2025, Regentis Biomaterials became public on NASDAQ.
Business overview
Regentis Biomaterials is a tissue-repair company focused on developing and commercializing a hydrogel platform for damaged tissue regeneration. The company's core product, GelrinC, is a cell-free, off-the-shelf hydrogel implant designed for orthopedic treatments, specifically for repairing painful injuries to articular knee cartilage. GelrinC acts as a scaffold, gradually eroding as new cartilage forms, and is completely resorbed within 6 to 12 months. Regentis Biomaterials serves the healthcare and life sciences sectors, particularly providers, operating within the medical devices, medical treatment & therapeutics, and biomaterials & tissue engineering categories.
Strategic signal
In July 2026, Regentis Biomaterials received European regulatory approval for a new GelrinC manufacturing process, which increases production yield by 400%. This development is a significant signal to investors, indicating enhanced operational efficiency and scalability for their flagship product, positioning the company for a more robust commercial launch in Europe and strengthening its market presence in the cartilage repair sector.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent development for Regentis Biomaterials' GelrinC product?
- In July 2026, Regentis Biomaterials received European regulatory approval for a new manufacturing process for GelrinC, which is expected to increase production yield by 400%.
- What is the latest intellectual property development for Regentis Biomaterials?
- In July 2026, Regentis received a Japanese patent allowance, strengthening its global intellectual property portfolio for GelrinC with new proprietary manufacturing technology.
- What strategic move did Regentis Biomaterials make regarding its European commercial launch?
- In June 2026, Regentis announced plans to commence European surgeon training for GelrinC in knee cartilage repair, accelerating preparations for its commercial launch in the region.
- What was the outcome of Regentis Biomaterials' public offering?
- In December 2025, Regentis Biomaterials Ltd. announced the closing of its Initial Public Offering and commenced trading on NYSE.
- What was a key finding regarding GelrinC's long-term efficacy?
- In January 2026, Regentis' GelrinC established long-term durability of cartilage repair through quantitative MOCART evaluation.